Therapeutic Resistance to Anti-Estrogen Therapy in Breast Cancer

Recent development and approval of next-generation estrogen receptor-α (ER) antagonists to target ESR1-mutant breast cancer underscores the clinical importance of this evolvability and sets a new paradigm for the treatment of ER+ breast cancers.